Tunneling Nanotubes-Mediated Protection of Mesenchymal Stem Cells: An Update from Preclinical Studies

Thangavelu Soundara Rajan¹, Agnese Gugliandolo², Placido Bramanti² and Emanuela Mazzon²,∗

1 Department of Biotechnology, School of Life Sciences, Karpagam Academy of Higher Education, Coimbatore 641021, India; tsrajanpillai@gmail.com
2 IRCCS Centro Neurolesi “Bonino-Pulejo”, Via Palermo, Contrada Casazza S.S.113, 98124 Messina, Italy; agnese.gugliandolo@irccsme.it (A.G.); placido.bramanti@irccsme.it (P.B.)
∗Correspondence: emanuela.mazzon@irccsme.it; Tel.: +39-090-60128172

Received: 21 April 2020; Accepted: 12 May 2020; Published: 14 May 2020

Abstract: Tunneling nanotubes (TNTs) are thin membrane elongations among the cells that mediate the trafficking of subcellular organelles, biomolecules, and cues. Mesenchymal stem cells (MSCs) receive substantial attention in tissue engineering and regenerative medicine. Many MSCs-based clinical trials are ongoing for dreadful diseases including cancer and neurodegenerative diseases. Mitochondrial trafficking through TNTs is one of the mechanisms used by MSCs to repair tissue damage and to promote tissue regeneration. Preclinical studies linked with ischemia, oxidative stress, mitochondrial damage, inflammation, and respiratory illness have demonstrated the therapeutic efficacy of MSCs via TNTs-mediated transfer of mitochondria and other molecules into the injured cells. On the other hand, MSCs-based cancer studies showed that TNTs may modulate chemoresistance in tumor cells as a result of mitochondrial trafficking. In the present review, we discuss the role of TNTs from preclinical studies associated with MSCs treatment. We discuss the impact of TNTs formation between MSCs and cancer cells and emphasize to study the importance of TNTs-mediated MSCs protection in disease models.

Keywords: tunneling nanotubes; mesenchymal stem cells; mitochondria; cancer cells; preclinical studies

1. Introduction

Tunneling nanotubes (TNTs) are thin and long membrane elongations among the cells. They consist of F-actin and are about 50–1000 nm in width and 100 µm in length [1]. TNTs represent a novel form of intercellular connection for a longer distance through which calcium, proteins, microRNAs, subcellular organelles, and cellular vesicles are transferred from one cell to another cell [2]. Mesenchymal stem cells (MSCs) are stromal cells, nonhematopoietic in nature, and can be differentiated into multiple cell lineages. They can be isolated from dental tissue, bone marrow, adipose tissue, umbilical cord, placenta, and other resources. A variety of MSCs-secreted immunomodulatory factors and growth factors has been documented via exosomes/microvesicles [3]. Extensive preclinical studies have established the therapeutic role of MSCs and/or their secretome in different disease models. The secretory factors and the absence of major histocompatibility complex II (MHCII) and factors associated with T cells coactivation enables MSCs theoretically suitable for allogeneic transplantation in clinical studies [4]. MSCs exhibit their therapeutic efficacy in tissue engineering and regenerative medicine through four potential mechanisms: i) direct cell-to-cell signaling; ii) paracrine signaling with soluble secreted factors such as hormones and proteins; iii) homing of released exosomes or microvesicles that contain immunoregulatory molecules and other molecules including RNA; iv) mitochondrial trafficking via...
TNTs or microvesicles [5]. Apart from preclinical studies associated with ischemia, oxidative stress, mitochondrial damage, inflammation, and respiratory illness, MSCs formed TNTs with cancer cells where it has been demonstrated that TNTs enhance the chemoresistance property of tumor cells.

Despite a novel mechanism, a limited number of in vitro and in vivo studies have reported the TNTs-based mechanism of action of MSCs.

In the present review, we discuss TNTs-driven mitochondrial trafficking from preclinical models treated with MSCs. To collect research articles related to TNTs we performed PubMed and Google scholar searches using the following keywords: “Tunneling nanotubes” and “Mesenchymal stem cells”. We emphasize the importance to study the TNTs-based mechanism of action of MSCs in other preclinical models.

2. Preclinical Studies

2.1. Ischemia/Reperfusion Model

An in vitro study by Liu et al. observed that human bone marrow MSCs rescued human umbilical cord vein endothelial cells subjected to oxygen and nutrients deprivation-induced stress, an in vitro ischemia/reperfusion model. Apoptosis in the endothelial cells induced by dysfunctional mitochondria was abolished by shifting of the functional mitochondria from MSCs through TNTs-like cell protrusions [6]. A similar anti-apoptotic effect of TNTs-mediated mitochondrial transfer was noticed in oxidative stress-induced H9c2 cardiomyocytes treated with rat bone marrow MSCs [7].

An interesting study by Figeac et al. demonstrated that the oxidative stress microenvironment of the mouse cardiomyocytes triggered human adipose MSCs to secrete factors related to cardiac protection. Soluble factors including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), stromal cell-derived factor 1-alpha (SDF-1α), and monocyte chemotactic protein-3 (MCP-3) were increasingly released by MSCs into the mouse cardiomyocytes by TNTs. Moreover, engraftment of human adipose MSCs preconditioned with distressed mouse cardiomyocytes significantly increased the cardiac function with elevated angiogenesis in mice subjected to myocardial infarction, suggesting TNTs-driven protective mechanism of MSCs [8].

An in vitro study by Babenko et al. reported that human bone marrow MSCs rescued rat astrocytes and neuron-like PC12 pheochromocytoma cells from oxygen–glucose deprivation-induced oxidative stress and mitochondrial damage, respectively. In vivo data from the same study showed that MSCs ameliorated the neurological impairments of cerebral ischemic rats. Data from this study demonstrated that the mitochondrial impairment was nullified by the transfer of mitochondria from bone marrow MSCs via TNTs, which in turn re-established the bioenergetics of the damaged cells. It was found that the degree of mitochondrial transfer from MSCs was more efficient when injured astrocytes were associated with an elevated reactive oxygen species level. In the same study, it was reported that ischemia rats treated with bone marrow MSCs that overexpressed the mitochondrial Rho-GTPase 1 protein (Miro1) showed significant improvement. Miro1 is a calcium-dependent adaptor protein that favors mitochondrial trafficking through microtubules and TNTs [9].

A recent in vivo study showed enhanced activity of mitochondria which resulted in angiogenesis progression, microvasculature restoration, and improved neurological activity in ischemic stroke injured rats administered with rat bone marrow MSCs. TNTs-mediated mitochondrial transfer was noticed in the cerebrovascular system of ischemic rats exposed to MSCs engrafting [10]. Another recent in vitro study reported two formation stages of TNTs between human MSCs derived from the umbilical cord and oxidative stress-induced neonatal mouse cardiomyocytes. In the active formation stage (≤16 h in coculture), more TNTs were protruded from MSCs while in the mature and stable stage (>16 h in coculture), more TNTs were protruded from distressed cardiomyocytes. It was observed that TNTs-mediated mitochondrial transfer from MSCs inhibited the hypoxia-based apoptosis in cardiomyocytes only in the mature and stable stage, assuming morphological characteristics of TNTs may play a crucial role in mitochondrial transfer [11]. These data supported the earlier in vitro MSCs-rat
neonatal cardiomyocytes coculture study reported by Yang et al. In this study, it was observed that the initial TNTs formation was derived from MSCs while after 24 h of coculture, majority of TNTs (67%) were originated from rat cardiomyocytes. However, mitochondrial trafficking was unidirectional from MSCs TNTs. Interestingly, the authors found a small number of TNTs between rat cardiomyocytes and cardiac fibroblasts with no mitochondrial shift, suggesting the differential ability of cells to generate TNTs with other interconnected cells [12].

2.2. Chemotherapy and Other Stress-Induced Models

Feng et al. reported that human bone marrow MSCs recovered the hematopoietic potency of human umbilical cord endothelial cells induced with cytarabine in an in vitro chemotherapy-based stress model. The observed apoptosis reduction in endothelial cells was linked with the mitochondrial transfer of MSCs via TNTs. Simultaneously, the TNTs-mediated shift of mitochondria restored transmembrane migration and capillary angiogenic potency of endothelial cells exposed to cytarabine [13]. A study by Jiang et al. revealed that direct coculture of human-induced pluripotent stem cells (iPSC)-derived MSCs nullify the oxidative stress induced by rotenone in corneal epithelial cells through TNTs-based mitochondrial transfer. The results showed that the TNTs formation was related to nuclear factor κB-TNFα induced protein 2 signaling pathway triggered by oxidative inflammation in corneal epithelial cells. In addition, TNTs-mediated mitochondrial transfer was observed in vivo study where MSCs cultured on a corneal scaffold was transplanted to a rabbit corneal injury model developed by sodium hydroxide administration [14].

In another in vitro study, human adipose derived MSCs exposed to antioxidants N-acetyl-L-cysteine (NAC) and L-ascorbic acid 2-phosphate (AAP) rescued MSCs from reduced mitochondrial density and membrane potential, caused by hydrogen peroxide-induced oxidative stress via TNTs-based mitochondrial transfer. The expression of mitochondrial fragmentation protein, dynamin-related protein 1 (DRP1S616), was blocked by the transferred mitochondria [15].

2.3. Stress Model from MELAS Patients

A recent study reported that MSCs provide healthy mitochondria to the cells derived from mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) patients. MELAS is an infrequent genetic disease associated with mitochondrial dysfunction. This mitochondrial disease is developed by the occurrence of point mutation in the mitochondrial tRNALeu(UUR) gene. In that study, it was observed that human Wharton’s jelly mesenchymal stem cells (WJMSCs) protected human MELAS fibroblasts from mitochondrial stress elicited by rotenone through mitochondrial transfer by TNTs. Impairments in the mitochondrial respiratory chain including low bioenergetics and membrane potential induced by rotenone in MELAS fibroblasts were rectified by the healthy mitochondria of WJMSCs. Moreover, the results showed that inhibiting the actin polymerization by cytochalasin B resulted in blocking TNTs formation which terminated the mitochondrial shift from MSCs. These data highlighted the pivotal role of TNTs formation in MSCs-based protection [16].

2.4. Inflammatory and Respiratory Disease Models

Transfer of rat bone marrow MSCs mitochondria through TNTs was noticed in rat nucleus pulposus cells subjected to inflammation by interleukin 1β exposure. Inflammation-induced apoptosis was suppressed by TNTs-mediated mitochondria movement from MSCs. It is imperative to mention that MSCs-based cell protection was observed only in the direct coculture method and not in the indirect coculture method, suggesting the key role of TNTs between MSCs and inflamed nucleus pulposus cells [17]. These data supported an earlier study where human bone marrow MSCs were found to connect with human nucleus pulposus cells via TNTs on a direct coculture system which resulted in phenotypic changes in the latter. However, in this study, neither MSCs nor pulposus cells were subjected to any inflammatory induction or other modes of stress [18]. In another in vitro study,
unidirectional mode of cell-to-cell connection was observed between human MSCs and human vascular smooth muscle cells (VSMCs) in which mitochondria were transferred from VSMCs to MSCs through TNTs, and resulted in the increased proliferation of MSCs. No induction of MSCs differentiation was observed [19]. On the other hand, bi-directional cytoplasmic contents exchange was reported between human adipose derived MSCs and human peripheral T lymphocytes where TNTs were selectively originated from T cells [20]. These data suggested that TNTs formation and the cell-to-cell connection may be unidirectional or bi-directional and may depend on the microenvironment as well as the physiological nature of the interconnected cells.

In an in vivo study, administration of bone marrow MSCs from mouse and human displayed protective effect against mouse acute lung injury model via mitochondrial transfer by TNTs and microvesicles. In this study, it was demonstrated that the formation of TNTs and microvesicles was attributed to the Connexin-43 dependent gap junctional channels formed between MSCs and mouse alveolar epithelial cells [21]. Sinclair et al. investigated the TNTs formation capacity of MSCs derived from digested parenchymal lung tissue from healthy donors and bronchoalveolar lavage fluid derived from lung transplant recipient donors with human bronchial epithelial BEAS-2B cells. The results showed the formation of TNTs between MSCs and epithelial cells and that inhibiting the TNTs formation resulted in the dysregulated transfer of mitochondria and cytosolic contents into epithelial cells [22]. Ahmad et al. reported the protective effect of human bone marrow MSCs in in vivo asthma models of rotenone-induced airway epithelial injury and allergic airway inflammation and in vitro mice bronchial epithelial cells treated with conditioned medium derived from macrophages exposed to IL-13. The TNTs-mediated mitochondrial transfer was attributed to the protection elicited by MSCs. Increased mitochondrial transfer and anti-inflammatory responses were elicited by MSCs that overexpressed Miro1 protein. In addition, it was observed that shRNA mediated knockdown of tumor necrosis factor alpha induced protein 2 (TNFAIP2), a protein associated with TNTs formation, showed reduced TNTs synthesis by MSCs followed by decreased mitochondrial transfer into the epithelial cells [23].

Li et al. reported the protective efficacy of human iPSC and bone marrow MSCs in in vitro and in vivo model of cigarette smoke-induced lung damage. They noticed the transfer of mitochondria through TNTs by which MSCs attenuate the mitochondrial dysfunction in BEAS-2B cells and suppress the degree of alveolar destruction in the lungs of rats injured by cigarette smoke [24]. A study by Jackson et al. described the therapeutic effect of human bone marrow MSCs in Escherichia coli-induced in vitro and in vivo model of acute respiratory distress syndrome by TNTs-mediated mitochondrial transfer. Decreased level of inflammation and increased level of alveolar macrophages-driven phagocytosis, bacterial clearance, and functional recovery of injured lung tissue were noticed due to mitochondrial transfer from MSCs TNTs. Several pro-inflammatory cytokines including interleukin-1β, interleukin 6, tumor necrosis factor alpha (TNF-α), and Eotaxin were reduced while anti-inflammatory cytokines such as interleukin 4 and RANTES were increased after the mitochondrial transfer from MSCs [25]. It is imperative to mention here that in addition to TNTs, mitochondria and their components transfer may occur via exosomes/microvesicles secreted from MSCs into macrophages and other cells. Exosomes-mediated transfer of mitochondria has been reviewed elsewhere [26,27].

Yao et al. recorded the therapeutic effect of human iPSC-derived MSCs in mice subjected to asthmatic inflammation by ovalbumin treatment. TNTs-mediated mitochondrial transfer of MSCs significantly reduced the mitochondrial impairment as well as the expression of pro-inflammatory cytokines profile including interleukins 5, 13, and 33. In the same study, TNTs-mediated mitochondrial transfer of MSCs rescued the mitochondrial dysfunction in human BEAS-2B cells treated with cobalt (II) chloride (CoCl₂). In addition, data from this study showed that the expression of gap junction protein connexin 43 plays a crucial role in the formation of TNTs from MSCs [28].
2.5. Other Non-Cancer Models

TNTs-based bi-directional exchange of cytoplasmic components was observed between human MSCs and rat renal tubular cells. However, substantial transport occurred in the MSCs from rat cells. The presence of Tamm–Horsfall protein, a glycoprotein uniquely synthesized by renal tubular cells, in MSCs suggested the possibility of differentiation of MSCs into renal tubular cells [29]. CoCl2-induced mitochondrial dysfunction in PC12 cells was recovered by human iPSC-derived MSCs. Mitochondrial transfer from MSCs by TNTs significantly nullified the distressed mitochondrial indexes such as swelling and cristae degeneration in PC12 cells [30].

2.6. Cancer Models

TNTs-mediated mitochondrial transfer from MSCs protected cancer cells from death induced by drugs which is an undesired event. Exchange of cytoplasmic components through TNTs was observed between human stromal cells including MSCs and human cancer cell lines such as SKOV3 ovarian cancer cell line and MCF7 breast cancer cell line [31]. An important study by Polak et al. demonstrated TNTs establishment between primary B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells and human bone marrow MSCs. Prosurvival cytokines including IL 8 and MCP1/CCL2 were secreted by MSCs into BCP-ALL cells via TNTs signaling, which resulted in chemoresistance of BCP-ALL cells against prednisolone, a glucocorticoid drug used in cancer therapy to induce apoptosis [32].

Marlein et al. showed that the presence of NADPH oxidase 2-induced superoxide in human acute myeloid leukemia (AML) cells primed the human bone marrow MSCs to shift the mitochondria from the latter via TNTs in an in vitro coculture setup [33]. Recently, the same group demonstrated CD-38 dependent TNTs formation between human multiple myeloma cells and human bone marrow MSCs [34].

Jurkat cell line, a model for human primary T cell-ALL (T-ALL), reportedly found to exchange mitochondria by TNTs upon exposure to cancer chemotherapeutic drugs (methotrexate and cytarabine) with human bone marrow MSCs. As a result, Jurkat cells attained chemoresistance from drug-induced apoptosis. The TNTs-mediated mitochondrial transfer was abolished when the cells were exposed to an antibody, which neutralized the activity of intercellular adhesion molecule 1 [35]. A recent study reported that human bone marrow MSCs activated by reactive oxygen species rescued human acute lymphoblastic leukemia (ALL) cell lines from drug-induced apoptosis and cell death. The rescue was attributed to TNTs-based mitochondrial transfer from activated MSCs [36].

A summary of the study reported in this review is available in Table 1. The major effects of TNTs-mediated action of MSCs with injured and cancer cells are highlighted in Figure 1.

Table 1. Overview of the studies reported in this review regarding tunneling nanotubes (TNTs) trafficking in preclinical models associated with mesenchymal stem cells (MSCs) treatment.

| Field of Study       | MSCs Source               | Experimental Model                                                                 | Results                                                                 | Ref.        |
|----------------------|---------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------|------------|
| Ischemia/reperfusion | Human bone marrow MSCs    | Human umbilical vein endothelial cell exposed to OGD                                | Reduced apoptosis                                                      | [6]        |
| Ischemia/reperfusion | Rat bone marrow MSCs      | H9c2 rat ventricular cell line in vitro model of SI/R                               | Reduced apoptosis                                                      | [7]        |
| Ischemia/reperfusion | Human adipose MSCs        | *In vitro*: Mouse cardiomyocyte; *In vivo*: mouse subjected to MI                 | *In vitro*: increased release of cardioprotective soluble factors by MSCs; *In vivo*: greater cardiac function recovery associated with higher angiogenesis | [8]        |
| Ischemia/reperfusion | Human bone marrow MSCs    | *In vitro*: Rat astrocytes exposed to OGD and PC12 pheochromocytoma cells exposed to ethidium bromide; *In vivo*: Rats subjected to MCAO | *In vitro*: MSCs rescued astrocytes and PC12 cells from damage; *In vivo*: MSCs, especially those overexpressing Miro1, ameliorated neurological impairment | [9]        |
| Field of Study       | MSCs Source                                      | Experimental Model                                                                 | Results                                                                 | Ref.       |
|---------------------|-------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------|------------|
| Ischemia/reperfusion| Rat bone marrow MSCs                            | Rats subjected to MCAO                                                            | Increase in angiogenesis, improvements in functional recovery          | [10]       |
| Ischemia/reperfusion| Human umbilical cord MSCs                        | Neonatal mouse cardiomyocytes exposed to hypoxia/reoxygenation                     | Reduced apoptosis                                                      | [11]       |
| Ischemia/reperfusion| Rat bone marrow MSCs                            | Neonatal rat cardiomyocytes                                                       | Initial TNT formation derived from MSCs, while after 24h majority of    | [12]       |
|                     |                                                 |                                                                                    | TNTs derived from cardiomyocytes                                       |            |
| Chemotherapy        | Human bone marrow MSCs                           | Human umbilical cord vein endothelial cells treated with cytarabine               | Reduced apoptosis, restored transmembrane migration ability and         | [13]       |
|                     |                                                 |                                                                                    | angiogenic capacity of endothelial cells                               |            |
| Oxidative stress    | Human iPSC-derived MSCs                          | *In vitro*: Conveal epithelial cells exposed to rotenone;                         | *In vitro*: protection against rotenone oxidative stress;             | [14]       |
|                     |                                                 | *In vitro*: Rabbit model of conveal alkaline burn induced by sodium hydroside      | *In vitro*: beneficial effects for conveal wound recovery              |            |
| Oxidative stress    | Human adipose derived MSCs                       | MSCs exposed to hydrogen peroxide, N-acetyl-L-cysteine, and L-ascorbic acid 2-phosphate | Antioxidants increased mitochondrial mass and respiratory capacity      | [15]       |
| MELAS patients      | Wharton’s jelly MSCs                             | Human MELAS fibroblasts treated with rotenone                                    | Improved mitochondrial stress                                         | [16]       |
| Inflammation        | Rat bone marrow MSCs                             | Rat nucleus pulposus cells exposed to IL-1β                                      | Reduced apoptosis only in direct coculture                              | [17]       |
|                     | Human bone marrow MSCs                           | Human nucleus pulposus cells                                                      | TNTs formation in coculture system resulting in phenotypic changes in  | [18]       |
|                     |                                                 |                                                                                    | human nucleus pulposus cells                                          |            |
| Inflammatory disease| Human bone marrow MSCs                           | Human vascular smooth muscle cells                                                | Increased MSCs proliferation, but not differentiation                  | [19]       |
| Immunomodulation     | Human adipose derived MSCs                       | Human peripheral T lymphocytes                                                     | Bi-directional cytoplasmic content exchanges                            | [20]       |
| Lung injury         | Mouse and human bone marrow MSCs                 | Mouse acute lung injury model                                                      | Mitochondria transfer by TNTs exerted protective effects              | [21]       |
| Lung injury         | Human MSCs derived from digested paranchymal lung | Human bronchial epithelial BEAS-2B cells                                          | Formation of TNTs between MSCs and epithelial cells                    | [22]       |
|                     | tissue and from lung transplant recipients’ bronchial/bronchoalveolar lavage fluid |                                                                                   |                                                                         |            |
| Lung injury         | Human bone marrow MSCs                           | *In vivo*: Mous model of rotenone-induced airway epithelial injury and allergenic airway inflammation | Protection exerted by TNTs mitochondrial transfer. MSCs overexpressing Miro1 showed increased mitochondria transfer | [23]       |
|                     |                                                 | *In vivo*: Mous bronchial epithelial cells treated with conditioned medium derived from macrophages exposed to IL-13 | *In vivo*: attenuated mitochondrial dysfunction |                                                                         |            |
| Respiratory disease | Human iPSC-derived MSCs and bone marrow MSCs     | *In vivo*: Human bronchial epithelial BEAS-2B cells exposed to cigarette smoke     | *In vivo*: enhanced phagocytic capacity;                              | [24]       |
|                     |                                                 | *In vivo*: Rats injured by cigarette smoke                                         | *In vivo*: improved alveolar destruction                              |            |
| Respiratory disease | Human bone marrow MSCs                           | *In vivo*: Human monocyte-derived macrophages exposed to LPS or *Escherichia coli* | *In vivo*: attenuated mitochondrial dysfunction                        | [25]       |
|                     |                                                 | *In vivo*: Mous subjected to *Escherichia coli* pneumonia                          | *In vivo*: enhanced alveolar macrophages phagocytosis, decreased        |            |
|                     |                                                 |                                                                                    | inflammation, and functional recovery                                 |            |
| Respiratory disease | Human iPSC-derived MSCs                          | *In vivo*: Mous subjected to asthmatic inflammation by treatment with ovalbumin; | *In vivo*: Attenuated mitochondrial dysfunction and inflammation;      | [28]       |
|                     |                                                 | *In vivo*: Human bronchial epithelium cell line BEAS-2B cells treated with CoCl₂  | *In vivo*: Attenuated mitochondrial dysfunction                        |            |
| Human MSCs          | Rat renal tubular cells                          |                                                                                    | Bi-directional cytoplasmic content exchanges and MSCs differentiation   | [29]       |
| Mitochondria damage | Human iPSC-derived MSCs                          | PC12 cells treated with CoCl₂                                                       | Attenuated mitochondrial dysfunction                                  | [30]       |
| Cancer              | MSCs                                             | Human cancer cell lines, such as SKOV3 ovarian cancer cells and MCF7 breast cancer cells | Exchange of cytoplasmic components                                    | [31]       |
Table 1. Cont.

| Field of Study | MSCs Source | Experimental Model | Results | Ref. |
|----------------|-------------|--------------------|---------|-----|
| Cancer         | Human bone marrow MSCs | Primary B cell precursor acute lymphoblastic leukemia cells (BCP-ALL) | Chemoresistance of BCP-ALL to prednisolone | [32] |
| Cancer         | Human bone marrow MSCs | Acute myeloid leukemia cells | NADPH oxidase-2 derived superoxide drove mitochondrial transfer from MSCs to leukemic cells | [33] |
| Cancer         | Human bone marrow MSCs | Human multiple myeloma cells | CD-38 dependent TNTs formation | [34] |
| Cancer         | Human bone marrow MSCs | Human T cell acute lymphoblastic leukemia cell line Jurkat exposed to methotrexate and cytarabine | Chemoresistance from drug-induced apoptosis | [35] |
| Cancer         | Human bone marrow MSCs | Human acute lymphoblastic leukemia cell lines | Reduced drug-induced apoptosis | [36] |

CoCl₂, Cobalt (II) chloride; iPSC, induced pluripotent stem cells; MCAO, middle cerebral artery occlusion; MELAS, Mitochondrial myopathy, Encephalopathy, Lactic acidosis, and Stroke-like episodes; MI, myocardial infarction; Miro1, Mitochondrial Rho-GTPase 1; MSCs, mesenchymal stem cells; OGD, oxygen–glucose deprivation; SI/R, simulated ischemia/reperfusion.

Figure 1. Tunneling nanotubes (TNTs)-mediated effects of mesenchymal stem cells in injured cells and cancer cells.

3. Future Directions

TNTs-mediated protective mechanism of MSCs has been demonstrated predominantly in preclinical models associated with ischemia/reperfusion, mitochondrial dysfunction, oxidative stress, and asthmatic inflammation. MSCs showed enormous therapeutic efficiency against a wide variety of diseases. MSCs-based clinical trials have been increasing day by day [37]. Of note, TNTs-based intercellular communication has been described in the central nervous system [38]. The putative role of the TNTs-driven mitochondrial shift has been studied in rat cerebral ischemia model administered with human bone marrow MSCs [39]. Nevertheless, the primordial role of TNTs-mediated intercellular connection by MSCs has not been elucidated in many diseases including neurodegenerative diseases and autoimmune diseases. It is important to understand the possible exchange of mitochondria and other subcellular organelles and other secreted factors through TNTs in these disease microenvironments treated with MSCs. Accordingly, future studies shall be projected towards defining the role of TNTs in MSCs-treated disease models including neurodegenerative diseases and autoimmune diseases. Given the unidirectional and bi-direction mode of the TNTs-based cargo among cells, a study on the nature of microenvironment that favors TNTs establishment in different types of cells might help to extend the results to the clinical level. MSCs in cancer therapy remains elusive as there are reports for both therapeutic potency and cancer progression [40]. As TNTs are protruded from MSCs as well as cancer cells it is indispensable to understand the cues generated from both cells using TNTs as a bridge...
which eventually determines what subcellular contents or secreted factors shall be transferred and in what direction the cargo is. We believe that results from these future preclinical studies based on above-mentioned themes may have key impacts on MSCs-based clinical trials.

4. Conclusions

TNTs are a novel cargo route among cells through which subcellular organelles and secreted factors are transferred. Preclinical studies have demonstrated the TNTs-mediated protection of MSCs in a wide range of stress microenvironments. Mitochondria transfer from MSCs is predominant through TNTs which reframe the cancer cells to attain chemoresistance against drugs. Further preclinical studies are warranted to understand the key mechanisms underlying TNTs-driven protection of MSCs against a wide array of diseases that might be translated into clinical studies.

Author Contributions: Conceptualization, T.S.R., P.B., and E.M.; investigation, T.S.R. and A.G.; writing—original draft preparation, T.S.R. All authors have read and agreed to the published version of the manuscript.

Funding: The present article was supported by DST-FIST to Department of Biotechnology, Karpagam Academy of Higher Education (SR/FST/LS-1/2018/187; Dated 26/12/2018) and current research funds 2020, Ministry of Health, of IRCCS-Centro Neurolesi “Bonino-Pulejo”, Messina, Italy.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

| Acronym | Full Form |
|---------|-----------|
| TNTs    | Tunneling nanotubes |
| MSCs    | Mesenchymal stem cells |
| MHCII   | Major histocompatibility complex II |
| HGF     | Hepatocyte growth factor |
| VEGF    | Vascular endothelial growth factor |
| SDF-1α  | Stromal cell-derived factor-1α |
| MCP-3   | Monocyte chemotactic protein-3 |
| Miro1   | Mitochondrial Rho-GTase 1 |
| iPSC    | Induced pluripotent stem cells |
| NAC     | N-acetyl-L-cysteine |
| AAP     | L-ascorbic acid 2-phosphate |
| DRP1    | Dynamin-related protein 1 |
| MELAS   | Mitochondrial myopathy, Encephalopathy, Lactic acidosis, and Stroke-like episodes |
| WJMSCs  | Wharton’s jelly mesenchymal stem cells |
| VSMCs   | Vascular smooth muscle cells |
| TNF-α   | Tumor necrosis factor-alpha |
| CoCl₂   | Cobalt (II) chloride |
| BCP-ALL | B-cell precursor acute lymphoblastic leukemia |
| AML     | Acute myeloid leukemia |
| T-ALL   | T cell acute lymphoblastic leukemia |

References

1. Drab, M.; Stopar, D.; Kralj-Iglic, V.; Iglic, A. Inception Mechanisms of Tunneling Nanotubes. Cells 2019, 8. [CrossRef]
2. Dupont, M.; Souriant, S.; Lugo-Villarino, G.; Maridonneau-Parini, I.; Verollet, C. Tunneling Nanotubes: Intimate Communication between Myeloid Cells. Front. Immunol. 2018, 9, 43. [CrossRef]
3. Musial-Wysocka, A.; Kot, M.; Majka, M. The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. Cell Transplant. 2019, 28, 801–812. [CrossRef]
4. Machado Cde, V.; Telles, P.D.; Nascimento, I.L. Immunological characteristics of mesenchymal stem cells. Rev. Bras. De Hematol. E Hemoter. 2013, 35, 62–67. [CrossRef]
5. Spees, J.L.; Lee, R.H.; Gregory, C.A. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res. Ther. 2016, 7, 125. [CrossRef]
6. Liu, K.; Ji, K.; Guo, L.; Wu, W.; Lu, H.; Shan, P.; Yan, C. Mesenchymal stem cells rescue injured endothelial cells in an in vitro ischemia-reperfusion model via tunneling nanotube like structure-mediated mitochondrial transfer. *Microvasc. Res.* **2014**, *92*, 10–18. [CrossRef]  
7. Han, H.; Hu, J.; Yan, Q.; Zhu, J.; Zhu, Z.; Chen, Y.; Sun, J.; Zhang, R. Bone marrow-derived mesenchymal stem cells rescue injured H9c2 cells via transferring intact mitochondria through tunneling nanotubes in an in vitro simulated ischemia/reperfusion model. *Mol. Med. Rep.* **2016**, *13*, 1517–1524. [CrossRef] [PubMed]  
8. Figeac, F.; Lesault, P.F.; Le Coz, O.; Damy, T.; Soutkani, R.; Trebeau, C.; Schmitt, A.; Ribot, J.; Mounier, R.; Guguin, A.; et al. Nanotubular crosstalk with distressed cardiomyocytes stimulates the paracrine repair function of mesenchymal stem cells. *Stem Cells* **2014**, *32*, 216–230. [CrossRef] [PubMed]  
9. Babenko, V.A.; Silachev, D.N.; Popkov, V.A.; Zorova, L.D.; Pevzner, I.B.; Plotnikov, E.Y.; Sukhikh, G.T.; Zorov, D.B. Miro1 Enhances Mitochondria Transfer from Multipotent Mesenchymal Stem Cells (MMSC) to Neural Cells and Improves the Efficacy of Cell Recovery. *Molecules* **2018**, *23*. [CrossRef] [PubMed]  
10. Liu, K.; Guo, L.; Zhou, Z.; Pan, M.; Yan, C. Mesenchymal stem cells transfer mitochondria into cerebral microvasculature and promote recovery from ischemic stroke. *Microvasc. Res.* **2019**, *123*, 74–80. [CrossRef] [PubMed]  
11. Zhang, J.; Zhang, J.; Zhao, L.; Xin, Y.; Liu, S.; Cui, W. Differential roles of microtubules in the two formation stages of membrane nanotubes between human mesenchymal stem cells and neonatal mouse cardiomyocytes. *Biochem. Biophys. Res. Commun.* **2019**, *512*, 441–447. [CrossRef] [PubMed]  
12. Yang, H.; Borg, T.K.; Ma, Z.; Xu, M.; Wetzel, G.; Saraf, L.V.; Markwald, R.; Runyan, R.B.; Gao, B.Z. Biochip-based study of unidirectional mitochondrial transfer from stem cells to myocytes via tunneling nanotubes. *Biofabrication* **2016**, *8*, 015012. [CrossRef] [PubMed]  
13. Feng, Y.; Zhu, R.; Shen, J.; Wu, J.; Lu, W.; Zhang, J.; Zhang, J.; Liu, K. Human Bone Marrow Mesenchymal Stem Cells Rescue Endothelial Cells Experiencing Chemotherapy Stress by Mitochondrial Transfer Via Tunneling Nanotubes. *Stem Cells Dev.* **2019**, *28*, 674–682. [CrossRef] [PubMed]  
14. Jiang, D.; Gao, F.; Zhang, Y.; Wong, D.S.; Li, Q.; Tse, H.F.; Xu, G.; Yu, Z.; Lian, Q. Mitochondrial transfer of mesenchymal stem cells effectively protects corneal epithelial cells from mitochondrial damage. *Cell Death Dis.* **2016**, *7*, e2467. [CrossRef]  
15. Li, C.J.; Chen, P.K.; Sun, L.Y.; Pang, C.Y. Enhancement of Mitochondrial Transfer by Antioxidants in Human Mesenchymal Stem Cells. *Oxidative Med. Cell. Longev.* **2017**, *2017*, 8510805. [CrossRef]  
16. Lin, T.K.; Chen, S.D.; Chuang, Y.C.; Lan, M.Y.; Chuang, J.H.; Wang, P.W.; Hsu, T.Y.; Wang, F.S.; Tsai, M.H.; Huang, S.T.; et al. Mitochondrial Transfer of Wharton’s Jelly Mesenchymal Stem Cells Eliminates Mutation Burden and Rescues Mitochondrial Bioenergetics in Rotenone-Stressed MELAS Fibroblasts. *Oxidative Med. Cell. Longev.* **2019**, *2019*, 9537504. [CrossRef]  
17. Hu, J.; Deng, G.; Tian, Y.; Pu, Y.; Cao, P.; Yuan, W. An in vitro investigation into the role of bone marrow-derived mesenchymal stem cells in the control of disc degeneration. *Mol. Med. Rep.* **2015**, *12*, 5701–5708. [CrossRef]  
18. Lehmann, T.P.; Filipiak, K.; Juzwa, W.; Sujka-Kordowska, P.; Jagodzinski, P.P.; Zabel, M.; Glowacki, J.; Misterska, E.; Walczak, M.; Glowacki, M. Cocculture of human nucleus pulposus cells with multipotent mesenchymal stromal cells from human bone marrow reveals formation of tunnelling nanotubes. *Mol. Med. Rep.* **2014**, *9*, 574–582. [CrossRef]  
19. Vallabhaneni, K.C.; Haller, H.; Dumler, I. Vascular smooth muscle cells initiate proliferation of mesenchymal stem cells by mitochondrial transfer via tunneling nanotubes. *Stem Cells Dev.* **2012**, *21*, 3104–3113. [CrossRef]  
20. Matula, Z.; Nemeth, A.; Lorincz, P.; Szepesi, A.; Brozik, A.; Buzas, E.I.; Low, P.; Nemeth, K.; Uher, F.; Urban, V.S. The Role of Extracellular Vesicle and Tunneling Nanotube-Mediated Interellular Cross-Talk Between Mesenchymal Stem Cells and Human Peripheral T Cells. *Stem Cells Dev.* **2016**, *25*, 1818–1832. [CrossRef]  
21. Islam, M.N.; Das, S.R.; Emin, M.T.; Wei, M.; Sun, L.; Westphalen, K.; Rowlands, D.J.; Quadri, S.K.; Bhattacharya, S.; Bhattacharya, J. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. *Nat. Med.* **2012**, *18*, 759–765. [CrossRef] [PubMed]  
22. Sinclair, K.A.; Yerkovich, S.T.; Hopkins, P.M.; Chambers, D.C. Characterization of intercellular communication and mitochondrial donation by mesenchymal stromal cells derived from the human lung. *Stem Cell Res. Ther.* **2016**, *7*, 91. [CrossRef] [PubMed]  
23. Ahmad, T.; Mukherjee, S.; Pattnaik, B.; Kumar, M.; Singh, S.; Kumar, M.; Rehman, R.; Tiwari, B.K.; Jha, K.A.; Barhanpurkar, A.P.; et al. Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy. *EMBO J.* **2014**, *33*, 994–1010. [CrossRef] [PubMed]
Li, X.; Zhang, Y.; Yeung, S.C.; Liang, Y.; Liang, X.; Ding, Y.; Ip, M.S.; Tse, H.F.; Mak, J.C.; Lian, Q. Mitochondrial transfer of induced pluripotent stem cell-derived mesenchymal stem cells to airway epithelial cells attenuates cigarette smoke-induced damage. *Am. J. Respir. Cell Mol. Biol.* 2014, 51, 455–465. [CrossRef] [PubMed]

Jackson, M.V.; Morrison, T.J.; Doherty, D.F.; McAuley, D.F.; Matthay, M.A.; Kissenpfennig, A.; O’Kane, C.M.; Krasnodembskaya, A.D. Mitochondrial Transfer via Tunneling Nanotubes is an Important Mechanism by Which Mesenchymal Stem Cells Enhance Macrophage Phagocytosis in the In Vitro and In Vivo Models of ARDS. *Stem Cells* 2016, 34, 2210–2223. [CrossRef]

Montgomery, M.K. Mitochondrial Dysfunction and Diabetes: Is Mitochondrial Transfer a Friend or FoE? *Biology* 2019, 8. [CrossRef]

Hough, K.P.; Deshane, J.S. Exosomes in Allergic Airway Diseases. *Curr. Allergy Asthma Rep.* 2019, 19, 26. [CrossRef]

Yao, Y.; Fan, X.L.; Jiang, D.; Zhang, Y.; Li, X.; Xu, Z.B.; Fang, S.B.; Chiu, S.; Tse, H.F.; Lian, Q.; et al. Connexin 43-Mediated Mitochondrial Transfer of iPSC-MSCs Alleviates Asthma Inflammation. *Stem Cell Rep.* 2018, 11, 1120–1135. [CrossRef]

Plotnikov, E.Y.; Khryapenkova, T.G.; Galkina, S.I.; Sukhikh, G.T.; Zorov, D.B. Cytoplasm and organelle transfer between mesenchymal multipotent stromal cells and renal tubular cells in co-culture. *Exp. Cell Res.* 2010, 316, 2447–2455. [CrossRef]

Yang, Y.; Ye, G.; Zhang, Y.L.; He, H.W.; Yu, B.Q.; Hong, Y.M.; You, W.; Li, X. Transfer of mitochondria from mesenchymal stem cells derived from induced pluripotent stem cells attenuates hypoxia-ischemia-induced mitochondrial dysfunction in PC12 cells. *Neural Regen. Res.* 2020, 15, 464–472. [CrossRef]

Pasquier, J.; Guerrouahen, B.S.; Al Thawadi, H.; Ghiabi, P.; Maleki, M.; Abu-Kaoud, N.; Jacob, A.; Mirshahi, M.; Galas, L.; Rafii, S.; et al. Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance. *J. Transl. Med.* 2013, 11, 94. [CrossRef] [PubMed]

Polak, R.; de Rooij, B.; Pieters, R.; den Boer, M.L. B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment. *Blood* 2015, 126, 2404–2414. [CrossRef] [PubMed]

Marlein, C.R.; Zaitseva, L.; Piddock, R.E.; Robinson, S.D.; Edwards, D.R.; Shafat, M.S.; Zhou, Z.; Lawes, M.; Bowles, K.M.; Rushworth, S.A. NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts. *Blood* 2017, 130, 1649–1660. [CrossRef]

Marlein, C.R.; Piddock, R.E.; Mistry, J.J.; Zaitseva, L.; Hellmich, C.; Horton, R.H.; Zhou, Z.; Auger, M.J.; Bowles, K.M.; Rushworth, S.A. CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma. *Cancer Res.* 2019, 79, 2285–2297. [CrossRef]

Wang, J.; Liu, X.; Qiu, Y.; Shi, Y.; Cai, J.; Wang, B.; Wei, X.; Ke, Q.; Sui, X.; Wang, Y.; et al. Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells. *J. Hematol. Oncol.* 2018, 11, 11. [CrossRef]

Burt, R.; Dey, A.; Aref, S.; Aguair, M.; Akarca, A.; Bailey, K.; Day, W.; Hooper, S.; Kirkwood, A.; Kirschner, K.; et al. Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress. *Blood* 2019, 134, 1415–1429. [CrossRef]

Pittenger, M.F.; Discher, D.E.; Peault, B.M.; Phinney, D.G.; Hare, J.M.; Caplan, A.I. Mesenchymal stem cell perspective: Cell biology to clinical progress. *NPJ Regen. Med.* 2019, 4, 22. [CrossRef]

Agnati, L.F.; Guidolin, D.; Guescini, M.; Genedani, S.; Fuxe, K. Understanding wiring and volume transmission. *Int. J. Mol. Sci.* 2020, 21, 3481. [CrossRef]